A Non Interventional, Retrospective Study on Real World Usage and Treatment Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to the SIADH.
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2016
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia
- Focus Therapeutic Use
- Acronyms SAMPLE
- Sponsors Otsuka Pharmaceutical
- 15 Apr 2016 Status changed from recruiting to completed.
- 18 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.
- 18 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.